Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines

J. Simova, O. Sapega, T. Imrichova, I. Stepanek, L. Kyjacova, R. Mikyskova, M. Indrova, J. Bieblova, J. Bubenik, J. Bartek, Z. Hodny, M. Reinis,

. 2016 ; 7 (34) : 54952-54964.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011106

Grantová podpora
NT14461 MZ0 CEP - Centrální evidence projektů

Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in the organism for protracted periods of time and they can promote tumor development. Based on this emerging concept, we hypothesized that elimination of such potentially cancer-promoting senescent cells could offer a therapeutic benefit. To assess this possibility, here we first show that tumor growth of proliferating mouse TC-1 HPV-16-associated cancer cells in syngeneic mice becomes accelerated by co-administration of TC-1 or TRAMP-C2 prostate cancer cells made senescent by pre-treatment with the anti-cancer drug docetaxel, or lethally irradiated. Phenotypic analyses of tumor-explanted cells indicated that the observed acceleration of tumor growth was attributable to a protumorigenic environment created by the co-injected senescent and proliferating cancer cells rather than to escape of the docetaxel-treated cells from senescence. Notably, accelerated tumor growth was effectively inhibited by cell immunotherapy using irradiated TC-1 cells engineered to produce interleukin IL-12. Collectively, our data document that immunotherapy, such as the IL-12 treatment, can provide an effective strategy for elimination of the detrimental effects caused by bystander senescent tumor cells in vivo.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011106
003      
CZ-PrNML
005      
20190703134939.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.10712 $2 doi
035    __
$a (PubMed)27448982
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šímová, Jana $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0119399
245    10
$a Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines / $c J. Simova, O. Sapega, T. Imrichova, I. Stepanek, L. Kyjacova, R. Mikyskova, M. Indrova, J. Bieblova, J. Bubenik, J. Bartek, Z. Hodny, M. Reinis,
520    9_
$a Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in the organism for protracted periods of time and they can promote tumor development. Based on this emerging concept, we hypothesized that elimination of such potentially cancer-promoting senescent cells could offer a therapeutic benefit. To assess this possibility, here we first show that tumor growth of proliferating mouse TC-1 HPV-16-associated cancer cells in syngeneic mice becomes accelerated by co-administration of TC-1 or TRAMP-C2 prostate cancer cells made senescent by pre-treatment with the anti-cancer drug docetaxel, or lethally irradiated. Phenotypic analyses of tumor-explanted cells indicated that the observed acceleration of tumor growth was attributable to a protumorigenic environment created by the co-injected senescent and proliferating cancer cells rather than to escape of the docetaxel-treated cells from senescence. Notably, accelerated tumor growth was effectively inhibited by cell immunotherapy using irradiated TC-1 cells engineered to produce interleukin IL-12. Collectively, our data document that immunotherapy, such as the IL-12 treatment, can provide an effective strategy for elimination of the detrimental effects caused by bystander senescent tumor cells in vivo.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a bystander efekt $x účinky léků $7 D024201
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a stárnutí buněk $x účinky léků $7 D016922
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a cytokiny $x genetika $x metabolismus $7 D016207
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a interleukin-12 $x biosyntéza $x farmakologie $7 D018664
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a experimentální nádory $x genetika $x metabolismus $x terapie $7 D009374
650    _2
$a taxoidy $x farmakologie $7 D043823
650    _2
$a časové faktory $7 D013997
650    _2
$a tumor burden $x účinky léků $7 D047368
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sapega, Olena $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
700    1_
$a Imrichová, Terezie $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic. $7 _AN081460
700    1_
$a Stepanek, Ivan $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
700    1_
$a Kyjacova, Lenka $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
700    1_
$a Mikyskova, Romana $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
700    1_
$a Indrová, Marie $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0069868
700    1_
$a Bieblová, Jana $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0127729
700    1_
$a Bubeník, Jan, $u First Faculty of Medicine, Charles University in Prague, Prague 12000, Czech Republic. $d 1940- $7 jk01020086
700    1_
$a Bártek, Jiří, $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic. Danish Cancer Society Research Center, Copenhagen DK-2100, Denmark. Department of Medical Biochemistry and Biophysics, Science For Life Laboratory, Division of Translational Medicine and Chemical Biology, Karolinska Institute, 17121 Solna, Sweden. $d 1953- $7 xx0046271
700    1_
$a Hodný, Zdeněk $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic. $7 xx0074117
700    1_
$a Reiniš, Milan $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0083033
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 34 (2016), s. 54952-54964
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27448982 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20190703135129 $b ABA008
999    __
$a ok $b bmc $g 1288591 $s 1007918
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 34 $d 54952-54964 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NT14461 $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace